去势抵抗性前列腺癌的组织病理学证实镭-223治疗期间骨转移的变化：一例报告。
Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report.
作者信息
Dobashi Masato, Kouguchi Dai, Kanetsuna Yukiko, Ishii Junichiro
机构信息
Department of Urology, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka, 413-0012, Japan.
Department of Pathology, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka, 413-0012, Japan.
出版信息
Urol Case Rep. 2020 May 3;32:101230. doi: 10.1016/j.eucr.2020.101230. eCollection 2020 Sep.
Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223. Although the patient ultimately died from causes unrelated to the treatment before starting the third treatment course, we observed that radium-223 was more effective in areas closer to the bone cortex than in deeper tumor regions. Through histopathological analysis, we provide important mechanistic insights on the therapeutic effect of radium-223 in human prostate cancer bone metastases.
镭-223用于治疗伴有骨转移的去势抵抗性前列腺癌。在此，我们报告一例76岁男性患者，其被诊断为伴有骨转移的去势抵抗性前列腺癌，并开始接受镭-223治疗。尽管患者在开始第三个疗程之前最终死于与治疗无关的原因，但我们观察到镭-223在靠近骨皮质的区域比在更深的肿瘤区域更有效。通过组织病理学分析，我们对镭-223在人类前列腺癌骨转移中的治疗效果提供了重要的机制性见解。
Zotero 插件